Kinarus Therapeutics Holding A/  CH1330780979  /

uratis acquires, licenses, distributes, and promotes medicines for the treatment and/or prevention of orphan and specialty diseases in Switzerland that have been developed and brought to market by third party pharmaceutical companies. Curatis has exclusive distribution rights for more than 30 different drugs in Switzerland – many of them orphan disease and specialty disease medicines. This underlines Curatis' position in the Swiss orphan drug market. Curatis has set the goal of significantly increasing the number of third-party drugs under contract in Switzerland. In addition, Curatis aims to secure distribution rights for drugs in major European markets such as Germany, France, the UK, and Italy, reflecting a clear vision for growth and market expansion. In the medium to long term, Curatis expects to launch its own products if its development projects gain regulatory approval. Curatis expects this expansion strategy to be supported by the increased visibility and funding opportunities associated with becoming a part of a publicly listed group.